Trial
NCT05744739
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI); Effector Therapeutics
Condition
Acute Myeloid Leukemia
Intervention
Biospecimen Collection
Why stopped
Premature withdrawal of investigational product per study sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11